Insulin Glargine; Lixisenatide Patent Expiration
Insulin Glargine; Lixisenatide is Used for improving glycemic control in type 2 diabetes mellitus patients. It was first introduced by Sanofi-Aventis Us Llc
Insulin Glargine; Lixisenatide Patents
Given below is the list of patents protecting Insulin Glargine; Lixisenatide, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Soliqua 100/33 | US9950039 | Insulin glargine/lixisenatide fixed ratio formulation | Dec 10, 2035 | Sanofi-aventis Us |
Soliqua 100/33 | US9717852 | Cartridge holder and pen-type injector | Apr 08, 2033 | Sanofi-aventis Us |
Soliqua 100/33 | US9821032 | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin | May 09, 2032 | Sanofi-aventis Us |
Soliqua 100/33 | US10029011 | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine | Nov 11, 2030 | Sanofi-aventis Us |
Soliqua 100/33 | US9707176 | Pharmaceutical composition comprising a GLP-1 agonist and methionine | Nov 11, 2030 | Sanofi-aventis Us |
Soliqua 100/33 | US10117909 | Combination of an insulin and a GLP-1 agonist | Oct 09, 2029 | Sanofi-aventis Us |
Soliqua 100/33 | US9526764 | Combination of an insulin and a GLP-1-agonist | Oct 09, 2029 | Sanofi-aventis Us |
Soliqua 100/33 | US7918833 | Pen-type injector | Sep 23, 2027 | Sanofi-aventis Us |
Soliqua 100/33 | US8679069 | Pen-type injector | Apr 12, 2025 | Sanofi-aventis Us |
Soliqua 100/33 | US8512297 | Pen-type injector |
Sep 15, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9561331 | Drive mechanisms suitable for use in drug delivery devices |
Aug 28, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug 19, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9533105 | Drive mechanisms suitable for use in drug delivery devices |
Aug 17, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9604009 | Drive mechanisms suitable for use in drug delivery devices |
Aug 16, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US8992486 | Pen-type injector |
Jun 05, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9011391 | Pen-type injector |
Mar 26, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US8556864 | Drive mechanisms suitable for use in drug delivery devices |
Mar 03, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US8603044 | Pen-type injector |
Mar 02, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9233211 | Relating to a pen-type injector |
Mar 02, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9408979 | Pen-type injector |
Mar 02, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9526844 | Pen-type injector |
Mar 02, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9604008 | Drive mechanisms suitable for use in drug delivery devices |
Mar 02, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9610409 | Drive mechanisms suitable for use in drug delivery devices |
Mar 02, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9775954 | Pen-type injector |
Mar 02, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | US9827379 | Drive mechanisms suitable for use in drug delivery devices |
Mar 02, 2024
(Expired) | Sanofi-aventis Us |
Soliqua 100/33 | USRE45313 | Exendin variant peptides |
Jul 12, 2020
(Expired) | Sanofi-aventis Us |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Insulin Glargine; Lixisenatide's patents.
Latest Legal Activities on Insulin Glargine; Lixisenatide's Patents
Given below is the list recent legal activities going on the following patents of Insulin Glargine; Lixisenatide.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jun, 2024 | US9526764 |
Payment of Maintenance Fee, 4th Year, Large Entity | 20 Apr, 2022 | US10117909 |
Payment of Maintenance Fee, 4th Year, Large Entity | 12 Jan, 2022 | US10029011 |
Payment of Maintenance Fee, 4th Year, Large Entity | 06 Oct, 2021 | US9950039 |
Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jun, 2020 | US9526764 |
Patent Issue Date Used in PTA Calculation Critical | 06 Nov, 2018 | US10117909 |
Recordation of Patent Grant Mailed Critical | 06 Nov, 2018 | US10117909 |
Issue Notification Mailed Critical | 17 Oct, 2018 | US10117909 |
Dispatch to FDC | 01 Oct, 2018 | US10117909 |
Application Is Considered Ready for Issue Critical | 01 Oct, 2018 | US10117909 |